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when PGRN KO (knock-out) mice and wild type (WT) mice were chal-
lenged using ovalbumin injections and nasal sprays to induce lung in-
ﬂammation, the PGRN KO mice developed a Gaucher-like phenotype.
While the level of GCase activity in the KO mice cells was unaffected,
GCase was found aggregated with LIMP2 in the cytoplasm co-localized
with the autophagy marker LC3. They demonstrated that this defect isIn 1955, Christian de Duve discovered a novel organelle packaged
with hydrolytic enzymes for which he coined the terminology ‘lyso-
some’ (De Duve et al., 1955). Two decades later, he received the Nobel
prize for this work and more than six decades later, our knowledge of
the lysosome as an organelle for end-point degradation has expanded
enormously to one that plays a central role in cellular metabolism, impli-
cated not only in rare lysosomal storage diseases but also in common and
complex diseases such as Parkinson's disease, dementia, and cancer
(Coutinho & Alves, 2016). In this issue of EBioMedicine, Jian, Tian,
Hettinghouse, et al. (http://dx.doi.org/10.1016/j.ebiom.2016.10.010)
presented novel ﬁndings on progranulin (PGRN), a growth factor with
anti-inﬂammation properties, that also functions as a co-chaperone
with the heat shock protein HSP70 disaggregation system. During stress,
PGRN-HSP70 prevents the aggregation of lysosomal glucocerebrosidase
(GCase) and lysosomal integral membrane protein LIMP2 in the cyto-
plasm, and facilitates their trafﬁcking to the lysosome. These ﬁndings
have implications in Gaucher disease (GD), an autosomal recessively
inherited and most prevalent lysosomal storage disease, and demon-
strate the myriad of important cellular physiological functions of
the lysosome, in addition to serving as the cell's ‘waste bin’.
GD results from deﬁcient GCase (GBA1, EC3.2.1.45). Three clinical
forms of GD have been described: Type 1, non-neuropathic, Type 2,
acute neuropathic, and Type 3, sub-acute neuropathic (Beutler &
Grabowski, 2001). GD may also result from deﬁcient saposin C
(Tamaro et al., 2012) or LIMP2 (Reczek et al., 2007), the former is an ac-
tivator protein of GCase (Tamaro et al., 2012) and the latter is the recep-
tor protein for targetingGCase to the lysosome (Reczek et al., 2007). In a
previous study (Jian et al., 2016), these investigators reported that
serum PGRN level in GD patients is signiﬁcantly lower than that in
healthy controls, and four SNPs in the GRN gene that encodes PGRNom.2016.10.010.
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. This is an open access article undermay contribute to this low level. In the present study, they noted that
speciﬁc to GCase-LIMP2 since the localization of the lysosomal protein
marker LAMP2 (lysosomal associated membrane protein 2) was unaf-
fected. In addition, LAMP2 and LIMP2 as well as GCase trafﬁcking to
the lysosomes in the WT mice were also unaffected.
Immunoprecipitation studies followed by MS and other analyses of
WT and PGRN KO mouse cells showed that an additional protein, the
heat shock protein HSP70, was involved. It was postulated that during
stress induced by ovalbumin or certain pathological conditions, PGRN
functions as a co-chaperone of HSP70 via the HSP70 disaggregation sys-
tem (Nillegoda & Bukau, 2015) that prevents GCase-LIMP2 aggregation
in the cytoplasm and facilitates their lysosomal localization. In PGRNKO
cells, this intricate stress-response is perturbed, and GCase-LIMP2 ends
up aggregated in the cytoplasm. Consequently, glucocerebroside sub-
strate accumulates in the lysosome, resulting in cytotoxicity and expres-
sion of Gaucher-like phenotype (Fig. 1). To prove their point, the
authors used siRNA to speciﬁcally suppress HSP70 in lipid-stimulated
stressed cells and noted a reduction of lysosomal GCase detection and
simultaneously GCase aggregation in the cytoplasm.
Because PGRN is a growth factor that has oncogenic activities, this
limits its application for potential treatment of GD. To this end, the au-
thors performed expression studies of PGRN cDNA deletion mutants
and a 98 amino acid of C-terminal PGRN, termed ‘Pcgin’ (PGRN C-
terminus for GCase Interaction) was identiﬁed that retains binding ca-
pacity to GCase and HSP70 without oncogenic activity. Pcgin treatment
led to signiﬁcant reduction in glucocerebroside storage and increase of
GCase localization and activity in Type 1 and Type 2 GD cultured skin ﬁ-
broblasts, as well as in ovalbumin challenged PGRN-KO mice.
As stated, future investigation with additional GD models are war-
ranted. As a macromolecule, however, Pcgin may not be effective for
treatment of Types 2 and 3 GD as it may be excluded by the blood
brain-barrier. Future direction should include expression of Pcgin as a
fusion with the eleven amino acid protein transduction domain of the
HIV-Tat protein or other cell penetrating peptides for potential perme-
ation to reach the brain (Gramlich et al., 2016; Campbell et al., 2014).
If successful, similar expression studies of PGRN are warranted since
its deﬁciency has been associated with neurodegenerative diseases in-
cluding Parkinson's disease, Alzheimer's disease, multiple sclerosis,
and amyotrophic lateral sclerosis (Petkau & Leavitt, 2014). As GD isthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Interaction of PGRN as a co-chaperone with HSP70, GCase, and LIMP2. (A) In healthy cells, GCase binds to its receptor protein LIMP1 for lysosomal trafﬁcking and localization.
(B) When ovalbumin is used to induce stress, PGRN serves as a co-chaperone with HSP70 in the HSP70 disaggregation system that prevents GCase-LIMP1 aggregation in the
cytoplasm and facilitates their trafﬁcking/localization to the lysosome. (C) In stressed PGRN KO cells, PGRN deﬁciency results in GCase-LIMP1 aggregation in the cytoplasm, GCase
deﬁciency in the lysosome, excessive glucocerebroside substrate accumulation, and cytotoxicity. (D) Pcgin treatment of PGRN KO cells and Gaucher Types 1 and 2 ﬁbroblasts results in
the delivery of GCase to the lysosome, restoration of lysosomal GCase activity, and degradation of glucocerebroside. PGRN, progranulin; HSP, heat shock protein; GCase,
glucocerebrosidase; LIMP2, lysosomal integral membrane protein 2; KO, knock-out; Pcgin, progranulin C-terminus for GCase interaction.
14 F.Y.M. Choy, C.L. Christensen / EBioMedicine 13 (2016) 13–14clinically heterogeneous and patients with identical genotypemay have
variable clinical phenotype (Beutler & Grabowski, 2001), it will also be
interesting to compare the level of PGRN among these patients.
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